All ASPIRIN SUMMARIES

ISSUE 2021 (14)

Aspirin Summaries Issue 14 : Aspirin and Migraine

Table of Contents

Download PDF

Aspirin summaries Issue 14: Aspirin and Migraine

Migraine is a common condition of the brain and its blood supply1, experienced by around 1 in 7 people worldwide,2. If not adequately managed a migraine attack can have a serious impact upon a person’s quality of life and their ability to fulfil their responsibilities and plans1. Women are two to three times more likely to experience a migraine than men2. Symptoms of a migraine include;

• A moderate to severe throbbing or pulsating headache often but not always one-sided
• Sensitivity to light and sound
• Nausea and vomiting
• Immobilised due to pain
• Aura; usually visual but can be sensory [e.g. pins and needles] or more rarely motor symptoms
• Red, tearing eye, miosis and ptosis, eyelid swelling, nasal congestion or runny nose, redness and sweating above the eyebrow1,2

To avoid chronic problems from over use of medication headache specialists usually advise only using migraine medication on two days a week or less1.

Management of acute migraine incudes avoiding triggers and where possible lifestyle changes along with simple analgesia such as aspirin (900 mg), paracetamol or ibuprofen along with anti-sickness medications such as prochlorperazine or metoclopramide. Triptans can also be used on their own or in combination with other pain medication2.

The American Headache Society recommend aspirin and other NSAIDS, nonopioid analgesics, acetaminophen or caffeinated analgesic combinations such as aspirin + acetaminophen + caffeine for mild-to-moderate migraine attacks and keeping migraine-specific agents (triptans, dihydroergotamine) for moderate to severe attacks and mild to moderate attacks not effectively managed by the simple analgesics4.

A Cochrane review concluded that.

‘Aspirin 1000 mg is an effective treatment for acute migraine headaches, similar to sumatriptan 50 mg or 100 mg. Addition of metoclopramide 10 mg improves relief of nausea and vomiting. Adverse events were mainly mild and transient, and were slightly more common with aspirin than placebo, but less common than with sumatriptan 100 mg.’

 

The authors suggest aspirin with metoclopramide as a first line therapy for migraine with those that don’t respond trying an alternative therapy.

Migraine is further classified according to the frequency of attacks. Episodic migraine occurs less than 15 days a month whilst those experiencing chronic migraine experience headache on at least 15 days in a month with features of migraine on at least 8 days a month for 3 or more months2.

Menstrual migraine affects around 20-25% of women with migraine with approximately 22-70% of patients requiring specialist care5. They tend to cause a much greater level of disability than non-menstrual migraines5.

Aspirin should not be offered to young people under 16 years of age due to the risk of Reye’s syndrome nor for migraine in pregnant or breast feeding women2.

References

1. Konstantinos S, Vikelis M and Rapoport A. Acute care and treatment of migraine. J Neuro–Ophthalmol 2020; 40: 472-484

2. NICE Migraine CKS accessed 23/02/21 @ https://cks.nice.org.uk/topics/migraine/

3. Kirthi V, Derry S and Moore RA. Aspirin with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev. 2013;4:CD008041 https://doi.org/10.1002/14651858.CD008041.pub3

4. The American Headache Society. The American Headache Society position statement on integrating new migraine treatments into clinical practice. Headache 2019: 59:1-18. https://doi.org/10.1111.head.13456

5. Vetvik KG and MacGregor EA. Menstrual migraine: a distinct disorder needing greater recognition. The Lancet Neurology. 2021 Feb 15. DOI:https://doi.org/10.1016/S1474-4422(20)30482-8

 

Over-the-counter treatment for chronic migraine.

In this review of USA over-the -counter (OTC) medication for migraine the authors look at the evidence and effectiveness for various OTC therapies in their ability to reduce the severity and duration of a migraine attack. The authors suggest OTC medication can be more cost effective and maybe easier to use and better tolerated.

Within their review of the literature of a variety of OTC medications the authors look at aspirin. They draw on evidence from an updated Cochrane review (2013) in which aspirin is found to have similar efficacy and a more favourable safety profile when compared with sumatriptan 50 mg or 100 mg. Aspirin can be used with metoclopramide to reduce nausea and vomiting. The reviewers also cite promising evidence for aspirin as a prophylactic agent in preventing migraines but point out that further work is required to find the best dose for this.

For further information please see:

Peck J, Urits I, Zeien J et al. A comprehensive review of over-the counter treatment for chronic migraine headaches. Current Pain and Headache reports. 2020; 24: 19 https://doi.org/10.1007/s11916-020-00852-0

 

Aspirin and clopidogrel versus aspirin alone for the prevention of new onset migraine following transcatheter closure of atrial septal defects (CANOA) trial

The aim of this analysis of a randomised double-blind Canadian trial was to determine how long clopidogrel should be added to aspirin in order to reduce new-onset migraine in people who have undergone atrial septal defect (ASD) closure.  They found from an analysis of 171 patients that new-onset migraine after ASD closure occurs in approximately 15% of patients and is usually an early transient problem which will resolve for most people within 6-12 months.

Headache events were assessed using a structured migraine headache questionnaire, including a disability score, at 3, 6 and 12 months.

They found adding clopidogrel (75 mg daily) to aspirin (80 mg daily) three months after transcatheter ASD closure does significantly reduce the incidence of new onset migraine attacks. However no significant rebound effect was seen when clopidogrel was stopped at 3 months, with aspirin continued to 12-month follow-up at the investigator’s discretion, supporting the early discontinuation of dual antiplatelet therapy.

For further information please see:

Wintzer-Wehekind J, Horlick E, Imbrahim R et al. Effect of clopidogrel and aspirin versus aspirin alone on migraine headaches after transcatheter atrial septal defect closure. One-year results of the CANOA Randomized clinical trial. JAMA Cardiol. 2021;6(2):209-213. doi:10.1001/jamacardio.2020.4297 https://jamanetwork.com/journals/jamacardiology/article-abstract/2770703

 

Aspirin as a low cost well tolerated option for migraine management.

In this review article the authors describe migraine as a common and debilitating disorder and explain the role of aspirin as a well-tolerated and cost-effective treatment strategy. They review evidence for high-dose aspirin at doses between 900 and 1300 mg taken when symptoms begin as an effective, safe therapy for acute migraine and cite evidence that low-dose aspirin (81 to 325 mg) maybe effective and safe for treating recurrent migraine.

The authors conclude:

“The relatively favourable side effect profile of aspirin and extremely low costs compared with other prescription drug therapies may provide additional options for primary healthcare providers in the treatment of both acute and recurrent migraine headaches.”

For further information please see:

Biglione B; Gitin A, Gorelick PB and Hennekens C. Aspirin in the treatment and prevention of migraine headaches: Possible additional clinical options for primary healthcare providers. The American Journal of Medicine. 2020, 133:412-416. https://doi.org/10.1016/j.amjmed.2019.10.023

 

Review finds unmet needs for people with migraine in East Asia

This review paper describes studies undertaken after the first edition of the International Classification of Headache Disorders in 1988 until January 2019 that report on prevalence, human and economic burden and the management of migraine in China, Japan and South Korea.

From an initial 1337 publications found on MEDLINE and EMBASE databases 41 met the inclusion criteria. The one-year prevalence of migraine in adults ranged from 6-14%. The studies indicated that migraine resulted in significant disability and impact on quality of life for those who experienced it, but this was coupled with a relatively low level of disease awareness and diagnosis. The studies also found that prescription medicine use was low and that over the counter medications were more commonly used to treat migraine.

The authors conclude:

“There are substantial unmet needs for migraine with regard to appropriate diagnosis, and better management of and therapies for treatment of migraine across East Asia. However, more recent evidence is required to confirm current unmet needs in each country.”

For further information please see:

Takeshima T, Wan Q, Zhang Y et al. Prevalence, burden, and clinical management of migraine in China, Japan, and South Korea: a comprehensive review of the literature. The Journal of Headache and Pain. 2019 20:111 https://doi.org/10.1186/s10194-019-1062-4

 

Low-dose aspirin for migraine prophylaxis in pregnant women.

Migraine often improves or disappears during pregnancy but a significant link between migraine and pre-eclampsia and vascular complications such as stroke has been established. The antithrombotic action of low-dose aspirin helps regulate endothelial function thus improving vascular resistance.

This paper explores the potential role for low-dose aspirin for reducing vascular complications and migraine in pregnancy.  The authors call for future research to explore the role of low-dose aspirin in pregnant women who experience migraine attacks and suggest that:

“Simple, inexpensive primary preventive interventions could have major consequences in this high-risk group.”

For further information please see:

Liu X. and Gong Y. The potential protective role of aspirin against migraine in pregnant women. Medical Science Monitor: International Medical Journal of experimental and Clinical Research. 2020; 26: e923959-1e923959-6 doi:10.12659/MSM.923959 https://pubmed.ncbi.nlm.nih.gov/32740647/

 

Antithrombotic therapy for people with refractory migraine and antiphospholipid antibodies

Headache, particularly migraine is a common symptom in people with antiphospholipid syndrome (APS).  APS, a systemic autoimmune condition in which people have antiphospholipid antibodies, is linked to an increased risk of arterial and venous blood clots. It may also be the reason for an association between migraine and stroke. This small, retrospective study, with 75 patients, was designed to investigate the effect of a trial of antithrombotic therapy for the symptomatic relief of refractory migraine in people who have antiphospholipid antibodies.

Patients were given aspirin or clopidogrel (initially aspirin unless contraindication or suboptimal response) and anticoagulants were added if necessary, according to the response to antiplatelets.

The author concludes:

“ Our data support consideration of a 2-4 week trial of antithrombotic therapy, usually starting with antiplatelet therapy, in aPL-positive patients with refractory migraine, particularly if other treatment options have been exhausted.”

For further information please see:

Schofield JR, Hughes HN, Birlea M and Hassell K.  A trial of antithrombotic therapy in patients with refractory migraine and antiphospholipid antibodies: A retrospective study of 75 patients.  Lupus 2021 DOI:10.1177/0961203320983913. https://pubmed.ncbi.nlm.nih.gov/33402037/

 

Corresponding authors

 

Disclaimers:

• The information, views and opinions expressed are not endorsed or approved bymembers ofThe Scientific Advisory Board unless otherwise stated.
• The Information section is compiled using current published information at the time of writing and whilst every effort has been made to avoid errors, professional clinical judgement is required to interpret the information given.  The information given is referenced clearly for further analysis as required.
• Every effort is made by the International Aspirin Foundation to see that no misleading or inaccurate data, statement or opinion appear. The International Aspirin Foundation cannot be held responsible for any errors or for any consequences arising from the use of the information.
• The International Aspirin Foundation, its associates and The Scientific Advisory Board accept no liability whatsoever for the consequences of any such inaccurate or misleading data, information, opinion or statement.
• Any information involving drug usage, should only be followed in conjunction with the drug manufacturer’s own published literature in their own country.
• Medical sciences evolve on a continual basis and therefore independent verification of the content should be made.
• The information, views, opinions and any other material provided should not be relied upon as a substitute to professional medical advice in relation to any medical condition. The International Aspirin Foundation, its associates and The Scientific Advisory Board accept no liability whatsoever for any consequences arising from any reliance placed on such information, views, opinions and other materials in lieu of professional medical advice.

 

 

Back to top

SHARE THIS ARTICLE

Facebook
Twitter
LinkedIn
As 14
Download the full summary as a PDF document.
Download PDF

Connect with us

Sign up to be part of the aspirin community and be the first to receive latest information.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Have something to say about aspirin?

Contact Us Here

Have something to say about aspirin?

Please fill in the form below and we will contact you with further information.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Djp

Daniel José Piñeiro

ASSOCIATE
Name
Daniel José Piñeiro
Academic Affiliations:
Full Professor of Medicine, Universidad de Buenos Aires, Argentina Trustee, Board of Trustees, American College of Cardiology
Professional Setting:
My academic experience includes more than 40 years as a practicing medical doctor, teacher, and researcher. I have fulfilled these appointments in settings of vital social engagement and impact, most notably at the Hospital de Clínicas “José de San Martín” of the Universidad de Buenos Aires, a public hospital with high academic recognition. Additionally, I currently hold the position of Full Professor of Medicine at that same University.
Academic Activities:
  • International Meetings Participations: 180
  • Books-Editor: 1
  • Books Chapters: 39
  • Refereed Full Articles: 118 (listed in Pubmed: 29)
  • Refereed Abstracts: 221
  • Editorial Boards: 10
Profesional Associations:
  • 2005 President, Sociedad Argentina de Cardiología.
  • 2011-2013 President, Inter-American Society of Cardiology.
  • 2011-2013 Member (ex-officio), Board of Directors, World Heart Federation
  • 2017-2018 Member (at large), Board of Directors, World Heart Federation
  • 2018-2021 Trustee, Board of Trustees, American College of Cardiology
Return to Scientific Advisory Board
Chia

John Chia

Name
John Chia MBBS (Spore), MRCP (UK), FAMS (Spore)
Academic Affiliations:

Adjunct Associate Professor DUKE-NUS Graduate Medical School,
Consultant Oncologist Curie Oncology Singapore,
Visiting Consultant National Cancer Centre Singapore.

Discipline:

Medical Oncology

Scientific Interests:
  • Aspirin as adjuvant therapy in established cancers
  • Adoptive T cell therapy and Dendritic cell vaccines in the treatment of solid tumors
  • Clinical Trial Design and Management
Declaration of Conflicts of Interest:

In the past 3 years, I have received consultant fees from Tessa Therapeutics, Aslan Pharmaceuticals, Novartis, and AstraZeneca.

I received grant support for investigator-initiated research from:

  • National Medical Research Council Singapore
  • Bayer AG

I hold shares in:  Roche, BMS, AstraZeneca, Incyte, Teva Pharmaceuticals, Trillium Therapeutics, Compugen, Arrowhead pharmaceuticals, Emergex, QuantumDx and Halozyme Therapeutics

Return to Scientific Advisory Board
Badimon

Lina Badimon

Name
Lina Badimon BSc, PharmD, PhD, FESC, FAHA
Academic Affiliations:
Director of the Cardiovascular Science Program (ICCC) at the Hospital Santa Creu and San Pau, IIB-Sant Pau; CIBER CV. Director of the Cardiovascular Research Chair of the Autonomous University of Barcelona and Director of the UNESCO Chair in Biomedical Sciences Training and Research.
Discipline:
Pharmacology, Cardiovascular Disease
Scientific Interests:
Cardio-metabolic diseases, thrombosis, atherosclerosis and ischemic heart disease
Declaration of Conflicts of Interest:

I received consultant and speakers fees from Amgen, AstraZeneca, Bayer, Lilly and Sanofi.

    Return to Scientific Advisory Board
    Ge

    Junbo Ge

    Name

    Junbo Ge

    Ge Junbo, male, was born in Wulian, Shandong province on Nov. 8, 1962. He is the member of Chinese Academy of Sciences, professor and doctoral supervisor. He received his doctor’s degree of Medicine from German Mayence University in 1993 and now works as the director for Shanghai Institute of Cardiovascular Disease and the Center for Stem Cells and Tissue Engineering, Fudan University. He is also the designate chairman of the Cardiovascular Disease Branch of Chinese Medical Association, council member of the Cardiovascular Angiography and Interventions Association, international consultant of the American Heart Association. In Dec. 2013, he was appointed as the vice president of Tongji University.

    Prof. Ge has been engaged in clinical and scientific research work of cardiovascular disease since 1987, and his research area covers the pathogenesis of coronary heart disease, early diagnosis and treatment plan optimization.

    Return to Scientific Advisory Board
    Langley

    Ruth Langley

    Name
    Ruth Langley PhD, FRCP
    Academic Affiliations:
    Professor of Oncology and Clinical Trials, MRC Programme Leader and Chair of the Cancer Group, MRC Clinical Trials Unit at UCL, honorary consultant in medical oncology at the Brighton and Sussex University Hospital.
    Discipline:
    Medical oncologist; trialist
    Scientific Interests:
    • Aspirin
    • Gastro-oesophageal malignancy
    • Transdermal oestrogen in the treatment of prostate cancer
    • Trials methodology
    Declaration of Conflicts of Interest:
    Has received honorarium from Bayer
    Return to Scientific Advisory Board
    Chan

    Andrew T Chan

    Name
    Andrew T. Chan MD, MPH
    Academic Affiliations:
    Chief, Clinical and Translational Epidemiology Unit, Vice Chair, Division of Gastroenterology, Massachusetts General Hospital, Boston, Co-leader, Cancer Epidemiology Program, Dana-Farber/Harvard Cancer Center, Boston.
    Discipline:
    Gastroenterology
    Scientific Interests:
    • The role of aspirin in the prevention of colorectal cancer and other cancers
    • The role of the gut microbiome in colorectal cancer and other chronic gastrointestinal diseases, including inflammatory bowel disease and diverticulitis
    • The role of diet and lifestyle in colorectal cancer and other chronic gastrointestinal cancers
    Declaration of Conflicts of Interest:

    AACR Honors Dr. Andrew T. Chan With 2019 AACR-Waun Ki Hong Award

    Click here to find the press release.

    I received consultant Bayer and Pfizer, Inc.

    I received grant support for investigator-initiated research from:

    • National Institutes of Health
    • National Cancer Institute
    • Crohn’s and Colitis Foundation
    • Bayer AG
    Return to Scientific Advisory Board
    Gaziano

    Mike Gaziano

    Name
    J Michael Gaziano MD, MPH
    Academic Affiliations:

    Professor of Medicine, Harvard Medical School; Chief Division of Aging, Brigham and Women’s Hospital; Director of Preventive Cardiology and Director of Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC), VA Boston Healthcare System.
    Discipline: Cardiology and Epidemiology

    Scientific Interests:
    I am a chronic disease epidemiologist with a particular interest in the roles that individual lifestyle choices (diet, exercise, smoking), metabolic factors (obesity, high cholesterol, and hypertension), and biochemical and genetic markers play on the risk of cardiovascular disease and other chronic illnesses. Also, of interest is the impact that vascular disease has on other organ systems, including cognitive dysfunction and renal disease. I have an interest in the design of large-scale trials and observational studies nested in large health care systems using big data analytic techniques.
    Declaration of Conflicts of Interest:

    I received consultant and speaker fees Bayer.

    I received grant support as a principal investigator or co-investigator for research from the VA, DOD, NIH, Merck and Kowa.

    Return to Scientific Advisory Board
    Rothwell

    Peter Rothwell

    PAST – CHAIR
    Name

    Peter M. Rothwell PhD, MD, FRCP, FMedSci

    Academic Affiliations:
    • Action Research Chair of Neurology, Nuffield Department of Clinical Neurosciences, University of Oxford;
    • Founding Director, Wolfson Centre for Prevention of Stroke and Dementia, University of Oxford;
    • Wellcome Trust Senior Investigator;
    • Emeritus NIHR Senior Investigator;
    • Theme Leader, Stroke and Vascular Dementia, NIHR Biomedical Research Centre, John Radcliffe Hospital, Oxford
    Discipline:
    Neurology and Stroke Medicine
    Scientific Interests:
    • Risks and benefits of aspirin;
    • Primary and secondary prevention of stroke;
    • Effects of blood pressure on the brain.
    Declaration of Conflicts of Interest:
    I received consultant and speakers fees from Bayer AG.
    CarloPatrono

    Carlo Patrono

    CHAIR
    Name
    Carlo Patrono MD, FESC, FRCP
    Academic Affiliations:
    Adjunct Professor of Pharmacology at the Catholic University School of Medicine in Rome (Italy) and at the Perelman School of Medicine of the University of Pennsylvania in Philadelphia (USA).
    Discipline:
    Clinical Pharmacology
    Scientific Interests:
    • Studying platelet activation and inhibition in diabetes mellitus
    • Studying platelet activation and inhibition in myeloproliferative neoplasms
    • Investigating the mechanism of action of low-dose aspirin in preventing colorectal cancer
    Declaration of Conflicts of Interest:

    I received consultant and speakers fees from Acticor Biotech,  Amgen,  Bayer, GlaxoSmithKline,  Tremeau,  Zambon.

    I received grant support for investigator-initiated research from:

    • AIFA (Italian Drug Agency)
    • Bayer AG
    • Cancer Research UK
    • European Commission, FP6 and FP7 Programmes

      Return to Scientific Advisory Board

      Have something to say about aspirin?

      We would like to hear from you and have a chat, and maybe feature you on our podcast. Please fill in the form below and we will contact you with further information.

      This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.